

Supplementary information

**Silencing-mediated enhancement of osteogenic differentiation by supramolecular ternary siRNA polyplexes comprising biocleavable cationic polyrotaxanes and anionic fusogenic peptides**

Takasuke Inada<sup>1</sup>, Atsushi Tamura<sup>2,\*</sup>, Masahiko Terauchi<sup>1,2</sup>, Satoshi Yamaguchi<sup>1</sup>, Nobuhiko Yui<sup>2</sup>

<sup>1</sup>Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo, Tokyo 113-8549, Japan.

<sup>2</sup>Department of Organic Biomaterials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan.

\*Corresponding author: A. Tamura (E-mail address: tamura.org@tmd.ac.jp)

**Table of contents**

- S1. Characterization of DMAE-SS-PRX
- S2. Stability of the complexes against polyanion exchange reaction
- S3. Cell viability
- S4. Reference


**S1. Characterization of DMAE-SS-PRX.** DMAE-SS-PRX composed of *N,N*-dimethylaminoethyl carbamate (DMAE)-modified  $\alpha$ -CDs as a cyclic molecule, cystamine-conjugated PEG (H<sub>2</sub>N-SS-PEG-SS-NH<sub>2</sub>,  $M_n = 4,910$ ,  $M_w/M_n = 1.13$ , degree of polymerization = 103) as an axle polymer, and *N*-carbobenzoxy-L-tyrosine as a stopper molecule was synthesized according to our previous report.<sup>1</sup> <sup>1</sup>H nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Avance III 400 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany). The number of threading  $\alpha$ -CDs in the PRX was calculated from the peak area between 3.1-4.0 ppm (-O-CH<sub>2</sub>-CH<sub>2</sub>-O- of PEG axle and H<sub>2</sub>, H<sub>3</sub>, H<sub>4</sub>, H<sub>5</sub>, and H<sub>6</sub> protons of the threaded  $\alpha$ -CD) and 4.77-4.95 ppm (H<sub>1</sub> proton of the threaded  $\alpha$ -CD) in the <sup>1</sup>H NMR spectrum of unmodified PRX (Fig. S1A). The number of DMAE groups modified onto the DMAE-SS-PRX was calculated from the peak area between 3.2 ppm (-NH-CH<sub>2</sub>-CH<sub>2</sub>-N(CH<sub>3</sub>)<sub>2</sub> of the DMAE carbamate) and 4.8-5.3 ppm (H<sub>1</sub> proton of the threaded  $\alpha$ -CD) in the <sup>1</sup>H NMR spectrum of DMAE-SS-PRX (Fig. S1B). The number of threading  $\alpha$ -CDs and the number of modified DMAE groups in DMAE-SS-PRX were determined to be 21.9 and 78.0, respectively. The  $M_{n,NMR}$  of DMAE-SS-PRX was calculated to be 36,500 based on the numbers of threaded  $\alpha$ -CDs and DMAE groups determined by <sup>1</sup>H NMR.

**S2. Stability of the complexes against polyanion exchange reaction.** The stability of the DMAE-PRX/siRNA polyplexes and GALA/DMAE-SS-PRX/siRNA ternary polyplexes against polyanion exchange reaction was evaluated by gel electrophoresis.<sup>1</sup> In this experiment, heparin (Sigma-Aldrich, Milwaukee, WI, USA) was used as the polyanion. The DMAE-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex solutions (N/P 10, Glu/P 0.2) were mixed with heparin solutions at various concentrations (1 to 1,000  $\mu$ g/mL) (final siRNA concentration was 2.5  $\mu$ M). The resulting solution was incubated at 37 °C for 1 h. Electrophoresis was then performed on a 2% agarose gel in TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA) at 100 V for 10 min.


**S3. Cell viability.** MC3T3-E1 cells were plated in a 96-well plate at a density of  $2.5 \times 10^4$  cells/cm<sup>2</sup> and incubated overnight. After the medium was replaced with fresh medium (90  $\mu$ L), the treatment solutions (10  $\mu$ L) were added and incubated for 48 h. For determining cell viability, Cell Counting Kit-8 reagent (Dojindo Laboratories, Kumamoto, Japan) (10  $\mu$ L) was added to each well. After incubation for 1 h at 37 °C, the absorbance at 450 nm was measured using a Multiskan FC plate reader (Thermo Fisher Scientific, Waltham, MA, USA). The cellular viability was calculated relative to the untreated cells.

#### **S4. Reference**


1. A. Tamura and N. Yui, *Biomaterials*, 2013, **34**, 2480–2491.



**Figure S1.**  $^1\text{H}$  NMR spectra of unmodified PRX in NaOD/D $_2$ O (A) and DMAE-SS-PRX in D $_2$ O (B).



**Figure S2.** Release of siRNA from DMAE-SS-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex (N/P 10, Glu/P 0.2) by the polyanion exchange with heparin.



**Figure S3.** Viability of MC3T3-E1 cells treated with DMAE-SS-PRX/siRNA polyplex (N/P 10) and GALA/DMAE-SS-PRX/siRNA ternary polyplex (N/P 10, Glu/P 0.2) at various concentration of siRNA for 48 h. Data are expressed as the mean  $\pm$  standard deviation (n = 5).